{"meta":{"query_hash":"a16778a58915","filters":{"venue":"JCO oncology advances."},"cohort_total":8,"direct_labels_cover":0,"predictions_cover":8,"exported":8,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/a16778a58915","api":"https://metacan.xera.ac/api/v1/cohort?venue=JCO+oncology+advances."},"results":[{"id":"W4404470663","doi":"10.1200/oa.24.00017","title":"Impact of Bone Metastasis in Stage IV Non–Small Cell Lung Cancer Treated With Durvalumab and Tremelimumab With or Without Chemotherapy: A Retrospective Analysis of the CCTG BR.34 Trial","year":2024,"lang":"en","type":"article","venue":"JCO oncology advances.","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Toronto; Princess Margaret Cancer Centre; Kingston Health Sciences Centre","funders":"","keywords":"Durvalumab; Tremelimumab; Chemotherapy; Medicine; Oncology; Bone metastasis; Stage (stratigraphy); Internal medicine; Lung cancer; Retrospective cohort study; Cancer; Metastasis; Immunotherapy; Biology","score_opus":0.01551241366614747,"score_gpt":0.35393185843658076,"score_spread":0.3384194447704333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404470663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891127,0.008304404,0.00018854234,0.00012954816,0.000030287183,0.00008649444,0.001358458,0.000004637524,0.0007849285],"genre_scores_gemma":[0.9971463,0.0007844508,0.000103160986,0.00010795858,0.000051544812,0.00005845183,0.0016598876,0.000005532586,0.00008258177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962084,0.0018343364,0.00051812886,0.0004858061,0.0007306973,0.00022252854],"domain_scores_gemma":[0.99337775,0.001866026,0.0035349021,0.00050152716,0.0003353788,0.00038441538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003972949,0.00023050036,0.0009852449,0.00034180415,0.00027274556,0.00089480024,0.00042703262,0.00041318397,0.00064265705],"category_scores_gemma":[0.0060589723,0.00023021153,0.0011569379,0.0011384913,0.00034522722,0.0004015086,0.00032141112,0.00056631054,0.00010085422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028831666,0.00012965898,0.9527343,0.0004088304,0.003136283,0.00022622243,0.00006453582,0.00044717823,0.0009859509,0.00012766097,0.0011362392,0.0117715085],"study_design_scores_gemma":[0.0026399803,0.0040798075,0.98550516,0.00009951705,0.0026016438,0.0008336156,0.000100152094,0.0007403517,0.0003481306,0.00011908723,0.0029066454,0.000026031279],"about_ca_topic_score_codex":0.0020624225,"about_ca_topic_score_gemma":0.0036944218,"teacher_disagreement_score":0.003972949,"about_ca_system_score_codex":0.00066768314,"about_ca_system_score_gemma":0.0006884748,"threshold_uncertainty_score":0.021011233},"labels":[],"label_agreement":null},{"id":"W4410141143","doi":"10.1200/oa.24.00023","title":"Underinvested, Under-Referred, and Underserved: Applying a Gender Equity Continuum Framework in Cancer Control Continuum Programs and Policies to Expand to Transgender and Nonbinary Populations","year":2025,"lang":"en","type":"article","venue":"JCO oncology advances.","topic":"LGBTQ Health, Identity, and Policy","field":"Psychology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Transgender; Health equity; Equity (law); Continuum of care; Gender equity; Health care; Political science; Public economics; Business; Public relations; Psychology; Sociology; Gender studies; Economics; Law","score_opus":0.1761066707733842,"score_gpt":0.5055179085219703,"score_spread":0.3294112377485861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410141143","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12437809,0.0048031746,0.027409447,0.7386924,0.0015806963,0.00063638913,0.00011000637,0.000082999875,0.10230677],"genre_scores_gemma":[0.9219419,0.0024135162,0.011031703,0.059191443,0.00039540275,0.00066316087,0.00004231597,0.00004342113,0.0042771157],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9815623,0.012188718,0.00037469543,0.00088680635,0.0020632527,0.0029242837],"domain_scores_gemma":[0.9865411,0.004986038,0.00089886546,0.00048592803,0.0014994169,0.0055886367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.030704612,0.00033021695,0.00040882593,0.0025203596,0.009811318,0.008578869,0.002930844,0.0035292443,0.004280029],"category_scores_gemma":[0.023276983,0.0003169118,0.0005280932,0.0011699754,0.02309506,0.008000228,0.017436994,0.010104319,0.0003017385],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069821835,0.0005363092,0.04175231,0.00039551916,0.000032142572,0.00041778,0.103726506,0.00096957217,0.00047757744,0.66724116,0.02768696,0.15669434],"study_design_scores_gemma":[0.00007841708,0.00038706503,0.039997708,0.0055856532,0.00008964475,0.00084353844,0.34251904,0.0033820658,0.0012039075,0.44606337,0.15971711,0.00013248422],"about_ca_topic_score_codex":0.03978972,"about_ca_topic_score_gemma":0.092705645,"teacher_disagreement_score":0.03978972,"about_ca_system_score_codex":0.0179465,"about_ca_system_score_gemma":0.065577045,"threshold_uncertainty_score":0.1623835},"labels":[],"label_agreement":null},{"id":"W4410294028","doi":"10.1200/oa-24-00088","title":"Patient-Reported Outcomes During Pelvic Radiation Therapy: A Secondary Analysis on Sexual Function From NRG-RTOG 1203","year":2025,"lang":"en","type":"article","venue":"JCO oncology advances.","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Radiation therapy; Sexual function; Adverse effect; Internal medicine; Logistic regression","score_opus":0.014943983264347822,"score_gpt":0.32403174198990464,"score_spread":0.3090877587255568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410294028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854071,0.0007524626,0.00038998952,0.00012121336,0.000024853192,0.00070254045,0.0099837,0.00002691744,0.0025911937],"genre_scores_gemma":[0.9924395,0.00011947677,0.0001856644,0.00012498438,0.00004263152,0.000685309,0.005921601,0.000010285421,0.0004705382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969373,0.00142304,0.0003564195,0.00027139674,0.00070832646,0.00030355423],"domain_scores_gemma":[0.99260885,0.0021948277,0.0034327987,0.00040447712,0.00077242206,0.00058650796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036394226,0.0004148382,0.0011730471,0.0011732326,0.0002974884,0.0005190977,0.00047479704,0.00036573206,0.0032550506],"category_scores_gemma":[0.005984833,0.00012026806,0.0025990522,0.0017579241,0.00024258367,0.0004340879,0.00062179717,0.00092597405,0.00035727723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02259434,0.0014414148,0.9427876,0.0005558455,0.0017658891,0.00012581526,0.00019810969,0.0011797049,0.0010694802,0.00009357325,0.0023111282,0.025877079],"study_design_scores_gemma":[0.0010225689,0.005616706,0.9902974,0.000034416305,0.00053646986,0.00017792723,0.000060297978,0.00058649725,0.00040944578,0.00005508991,0.0011885788,0.000014529996],"about_ca_topic_score_codex":0.0023878533,"about_ca_topic_score_gemma":0.0037715454,"teacher_disagreement_score":0.0036394226,"about_ca_system_score_codex":0.00072168827,"about_ca_system_score_gemma":0.00079565257,"threshold_uncertainty_score":0.019247353},"labels":[],"label_agreement":null},{"id":"W4411141142","doi":"10.1200/oa-24-00099","title":"Access to Cancer Treatment Clinical Trials for Racialized Adults and Older Adults: An Equity-Focused Rapid Scoping Review","year":2025,"lang":"en","type":"article","venue":"JCO oncology advances.","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Institute of Health Services and Policy Research; Canadian Cancer Society; University of Ottawa; Research Institute in Oncology and Hematology; University Health Network; Ottawa Hospital; CancerCare Manitoba; University of Regina; University of Victoria; University of Saskatchewan; Princess Margaret Cancer Centre; University of British Columbia; University of Toronto","funders":"","keywords":"Equity (law); Gerontology; Health equity; Clinical trial; Medicine; Psychology; Political science; Internal medicine; Pathology; Public health","score_opus":0.7425382517033181,"score_gpt":0.7649145283023298,"score_spread":0.022376276599011646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411141142","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00089369895,0.9895159,0.00084097084,0.0028212548,0.00064659247,0.0028571363,0.0004482708,0.000025328834,0.0019508391],"genre_scores_gemma":[0.0075705,0.98295903,0.0026899562,0.0017664321,0.00031063418,0.0040496117,0.00029728253,0.000016097154,0.00034034695],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9370086,0.02553511,0.024277672,0.0022357162,0.009643223,0.0012996792],"domain_scores_gemma":[0.70405203,0.23295091,0.0322289,0.0042722826,0.024226045,0.0022698937],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.064425424,0.0020013826,0.007682211,0.029659476,0.0024974025,0.010329679,0.003102542,0.004975096,0.0071142875],"category_scores_gemma":[0.27798036,0.0020156202,0.0076452373,0.024992824,0.0023091258,0.0098980265,0.006321534,0.0035340674,0.00084359397],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011511341,0.00003244951,0.0006945796,0.8836218,0.0021842862,0.00008351437,0.0013489235,0.00014553113,0.00013285392,0.001510243,0.0047918204,0.10533888],"study_design_scores_gemma":[0.000033400036,0.00003510329,0.00060782646,0.976999,0.0034461915,0.000058490677,0.00036985442,0.000046919493,0.000044894496,0.00038524775,0.017961001,0.000012142092],"about_ca_topic_score_codex":0.010631892,"about_ca_topic_score_gemma":0.025946094,"teacher_disagreement_score":0.9355746,"about_ca_system_score_codex":0.012192743,"about_ca_system_score_gemma":0.054165132,"threshold_uncertainty_score":0.34071827},"labels":[],"label_agreement":null},{"id":"W4412125650","doi":"10.1200/oa-24-00101","title":"Increasing Cervical Cancer Rates Among Women Age 35-54 Years in Canada: Age-Specific Cervical Cancer Incidence Trends in Canada, 1992-2022","year":2025,"lang":"en","type":"article","venue":"JCO oncology advances.","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Cervical cancer; Incidence (geometry); Medicine; Cancer; Demography; Gynecology; Obstetrics; Internal medicine; Sociology","score_opus":0.021748370339798165,"score_gpt":0.35348259145949573,"score_spread":0.3317342211196976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412125650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87117004,0.015756844,0.00081797363,0.0036329865,0.00013357587,0.00019295482,0.09713375,0.00019334457,0.010968462],"genre_scores_gemma":[0.97426546,0.004587109,0.0007903626,0.0004669708,0.000033543303,0.000062836145,0.017143939,0.00002045738,0.0026291644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911076,0.000031518503,0.00006032431,0.00012833203,0.00042426132,0.0002449025],"domain_scores_gemma":[0.99753124,0.00005160584,0.00040666867,0.000040903702,0.0016120377,0.00035756017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005950332,0.00037985976,0.00043156097,0.0026959928,0.0014886822,0.0011461845,0.0009909543,0.00049672177,0.001878878],"category_scores_gemma":[0.0019576717,0.00028851512,0.00086917984,0.005789807,0.0004245992,0.00057619746,0.00064695725,0.0009189209,0.00032202055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057077366,0.000022053355,0.9862623,0.00015215653,0.00011837809,0.000068277426,0.00032204136,0.00028388167,0.00017860024,0.00013040342,0.004751214,0.0076536047],"study_design_scores_gemma":[0.0000047309195,0.000010419252,0.9963768,0.000056945835,0.000045599827,0.00006085636,0.0003450751,0.0003399365,0.0000572321,0.000019411778,0.002675856,0.0000070955616],"about_ca_topic_score_codex":0.9946849,"about_ca_topic_score_gemma":0.9962607,"teacher_disagreement_score":0.030029325,"about_ca_system_score_codex":0.030029325,"about_ca_system_score_gemma":0.03599758,"threshold_uncertainty_score":0.21787906},"labels":[],"label_agreement":null},{"id":"W4415749836","doi":"10.1200/oa-25-00099","title":"Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for <i>BRCA1/2</i> or <i>PALB2</i> Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)","year":2025,"lang":"en","type":"article","venue":"JCO oncology advances.","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Gemcitabine; Pancreatic ductal adenocarcinoma; Cisplatin; Mutant; Pancreatic cancer; Adenocarcinoma; Chemotherapy","score_opus":0.052629116519449994,"score_gpt":0.42007127487289414,"score_spread":0.3674421583534441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415749836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9659007,0.0052360725,0.00114781,0.0025060747,0.0007627553,0.0039068214,0.0061184666,0.00078527344,0.013636068],"genre_scores_gemma":[0.9501982,0.005985453,0.004967245,0.004768869,0.0003590551,0.0048809955,0.01431085,0.00019113459,0.014338247],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99970067,0.00013411079,0.000015348574,0.00005463809,0.00002899702,0.00006630808],"domain_scores_gemma":[0.99952936,0.000056291923,0.00007495407,0.00003635901,0.00002210482,0.00028090962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014751484,0.0013437285,0.001312014,0.0005502339,0.00040331713,0.0012677436,0.001202968,0.0014560325,0.008488237],"category_scores_gemma":[0.0007868913,0.0004632686,0.0012643713,0.00055307534,0.00081782794,0.0011794874,0.0005955404,0.0039406726,0.0019488521],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58282626,0.067494445,0.0065025687,0.0018666745,0.002674492,0.00041023782,0.0003859948,0.0058233556,0.031268027,0.0020532168,0.03962372,0.259071],"study_design_scores_gemma":[0.7618548,0.20770265,0.0078898305,0.0001351968,0.00067057315,0.00062897865,0.00013749448,0.0026850824,0.0029282435,0.0010918592,0.0142229665,0.00005224224],"about_ca_topic_score_codex":0.0015934767,"about_ca_topic_score_gemma":0.0045672064,"teacher_disagreement_score":0.008488237,"about_ca_system_score_codex":0.0009203666,"about_ca_system_score_gemma":0.0017034132,"threshold_uncertainty_score":0.02839601},"labels":[],"label_agreement":null},{"id":"W4415937477","doi":"10.1200/oa-25-00053","title":"Enfortumab Vedotin in Patients With Previously Treated Advanced Breast Cancer in the Phase II EV-202 Study","year":2025,"lang":"en","type":"article","venue":"JCO oncology advances.","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Rash; Maculopapular rash; Breast cancer; Adverse effect; Regimen; Clinical endpoint; Phases of clinical research; Toxicity; Metastatic breast cancer","score_opus":0.01476243486084391,"score_gpt":0.4208429098651232,"score_spread":0.4060804750042793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415937477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912305,0.0041857553,0.00032600528,0.00021087419,0.00007640169,0.0008293017,0.0005314999,0.000045929955,0.0025636677],"genre_scores_gemma":[0.99299777,0.0021804518,0.00066119677,0.00051971525,0.00008206105,0.0006009647,0.0010967263,0.000011054012,0.0018499562],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998603,0.00007332503,0.0000069350117,0.000016523065,0.000017637709,0.000025253867],"domain_scores_gemma":[0.99984086,0.000031190302,0.00003670842,0.000013079508,0.0000116236615,0.00006642746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080212794,0.000369341,0.000541891,0.00011415329,0.00012002391,0.00044367058,0.00031606606,0.000384035,0.0016232436],"category_scores_gemma":[0.00040475803,0.00016124846,0.0004132517,0.00013783878,0.00019999724,0.00030363153,0.00015629068,0.0008944925,0.0002904387],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4684055,0.048885062,0.0383078,0.0020364823,0.0017074826,0.0005379529,0.00026526648,0.005429692,0.064522415,0.001121843,0.008867134,0.35991338],"study_design_scores_gemma":[0.44729373,0.4704777,0.04061016,0.00023809526,0.000968362,0.0009838564,0.00018889958,0.004874329,0.010595837,0.0007364893,0.022992188,0.000040368082],"about_ca_topic_score_codex":0.00036481014,"about_ca_topic_score_gemma":0.0014114194,"teacher_disagreement_score":0.0016232436,"about_ca_system_score_codex":0.00033790953,"about_ca_system_score_gemma":0.00055401237,"threshold_uncertainty_score":0.005430281},"labels":[],"label_agreement":null},{"id":"W4417008990","doi":"10.1200/oa-25-00055","title":"Detection of Molecular Residual Disease by Circulating Tumor DNA in Early-Stage Node-Negative Rectal Cancers (CCTG CO.28) Using a Tumor-Informed Assay","year":2025,"lang":"en","type":"article","venue":"JCO oncology advances.","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"NOSM University; Saskatchewan Cancer Agency; Ottawa Hospital; Kingston Health Sciences Centre; St. Paul's Hospital","funders":"","keywords":"Oxaliplatin; Colorectal cancer; Capecitabine; Chemotherapy; Total mesorectal excision; Circulating tumor DNA; Stage (stratigraphy); Minimal residual disease","score_opus":0.008381113569423145,"score_gpt":0.30131037101344077,"score_spread":0.2929292574440176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417008990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99565953,0.002088446,0.0003765374,0.000093070485,0.000014094825,0.00036079928,0.00038209005,0.000020330528,0.0010049408],"genre_scores_gemma":[0.99642354,0.00051561196,0.0013679599,0.00014191477,0.000017126378,0.0001820162,0.0008023402,0.000004815216,0.00054476643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99944144,0.00022362533,0.000023928736,0.00008576913,0.00016012415,0.00006508501],"domain_scores_gemma":[0.99915063,0.00020463028,0.0002481028,0.00007305467,0.00011956942,0.00020397699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010566904,0.0003205005,0.0005323554,0.00029035925,0.00020588802,0.00032101333,0.0003144191,0.00030473675,0.00071623037],"category_scores_gemma":[0.0012409118,0.00019548915,0.00018803556,0.00031907216,0.00053011096,0.00013964727,0.00014230316,0.0004238573,0.00012506341],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10254408,0.0028299524,0.5670076,0.0008774445,0.00038953024,0.00038644634,0.0003148088,0.0022732292,0.19264108,0.00023375,0.0025044817,0.12799758],"study_design_scores_gemma":[0.012811176,0.08656885,0.8608325,0.0000628198,0.00053086743,0.0016052286,0.00011526132,0.0024501665,0.030170862,0.00012590365,0.0046693776,0.000056943958],"about_ca_topic_score_codex":0.014654521,"about_ca_topic_score_gemma":0.057397816,"teacher_disagreement_score":0.014654521,"about_ca_system_score_codex":0.0010094657,"about_ca_system_score_gemma":0.0013223749,"threshold_uncertainty_score":0.029138446},"labels":[],"label_agreement":null}]}